<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>-associated autoantibodies hold promise as sensitive biomarkers for early detection of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Aberrant post-translational variants of proteins are likely to induce autoantibodies, and changes in O-linked glycosylation represent one of the most important <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-associated post-translational modifications (PTMs) </plain></SENT>
<SENT sid="2" pm="."><plain>Short aberrant O-<z:chebi fb="0" ids="18154">glycans</z:chebi> on proteins may introduce novel <z:chebi fb="0" ids="24396">glycopeptide</z:chebi> <z:chebi fb="0" ids="53000">epitopes</z:chebi> that can elicit autoantibodies because of lack of tolerance </plain></SENT>
<SENT sid="3" pm="."><plain>Technical barriers, however, have hampered detection of such <z:chebi fb="0" ids="24396">glycopeptide</z:chebi>-specific autoantibodies </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we have constructed an expanded <z:chebi fb="0" ids="24396">glycopeptide</z:chebi> array displaying a comprehensive library of <z:chebi fb="0" ids="24396">glycopeptides</z:chebi> and <z:chebi fb="0" ids="17089">glycoproteins</z:chebi> derived from a panel of human mucins (MUC1, MUC2, MUC4, MUC5AC, MUC6 and MUC7) known to have altered glycosylation and expression in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Seromic profiling of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> identified <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-associated autoantibodies to a set of aberrant <z:chebi fb="0" ids="24396">glycopeptides</z:chebi> derived from MUC1 and MUC4 </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative sensitivity of the array analysis was 79% with a specificity of 92% </plain></SENT>
<SENT sid="7" pm="."><plain>The most prevalent of the identified autoantibody targets were validated as authentic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunogens by showing expression of the <z:chebi fb="0" ids="53000">epitopes</z:chebi> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> using novel monoclonal antibodies </plain></SENT>
<SENT sid="8" pm="."><plain>Our study provides evidence for the value of <z:chebi fb="0" ids="24396">glycopeptides</z:chebi> and other PTM-<z:chebi fb="7" ids="16670">peptide</z:chebi> arrays in diagnostic measures </plain></SENT>
</text></document>